Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Adviye Ergul. (2003) Development of endothelin receptor antagonists as potential therapeutic agents. Expert Opinion on Therapeutic Patents 13:1, pages 33-44.
Read now
Read now
Robert J Anderson. (2002) Recent advances and developments in the treatment of acute renal failure. Expert Opinion on Therapeutic Patents 12:5, pages 645-655.
Read now
Read now
Ronald G Tilton, Tommy A Brock & Richard AF Dixon. (2001) Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension. Expert Opinion on Investigational Drugs 10:7, pages 1291-1308.
Read now
Read now
Articles from other publishers (9)
Christoph Boss, Martin H. Bolli & John Gatfield. (2016) From bosentan (Tracleer®) to macitentan (Opsumit®): The medicinal chemistry perspective. Bioorganic & Medicinal Chemistry Letters 26:15, pages 3381-3394.
Crossref
Crossref
K. Easwaramoorthi, A. Jeya Rajendran, K. Chennakesava Rao, Y. Arun, C. Balachandran, P. T. Perumal, Nobuhiko Emi, S. M. Mahalingam, V. Duraipandiyan & N. A. Al-Dhabi. (2015) Synthesis of novel 1,4-disubstituted 1,2,3-triazolo-bosentan derivatives – evaluation of antimicrobial and anticancer activities and molecular docking. RSC Advances 5:127, pages 105266-105278.
Crossref
Crossref
Alexander Treiber, Päivi Äänismaa, Ruben de Kanter, Stephane Delahaye, Marianne Treher, Patrick Hess & Patricia Sidharta. (2014) Macitentan Does Not Interfere with Hepatic Bile Salt Transport. Journal of Pharmacology and Experimental Therapeutics 350:1, pages 130-143.
Crossref
Crossref
Martin H. Bolli, Christoph Boss, Christoph Binkert, Stephan Buchmann, Daniel Bur, Patrick Hess, Marc Iglarz, Solange Meyer, Josiane Rein, Markus Rey, Alexander Treiber, Martine Clozel, Walter Fischli & Thomas Weller. (2012)
The Discovery of
N
-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-
N
′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist
. Journal of Medicinal Chemistry 55:17, pages 7849-7861.
Crossref
Crossref
Lewis J RubinChristopher Dufton & Michael J Gerber. (2005) Ambrisentan for pulmonary arterial hypertension. Future Cardiology 1:4, pages 425-432.
Crossref
Crossref
J. Dong, H. Han, B. Geng, X. Li, Z. Gong & K. Liu. (2005) Synthesis and evaluation of a new series of peptide-based endothelin receptor antagonists. Journal of Peptide Research 65:4, pages 440-444.
Crossref
Crossref
Jasper Dingemanse, Dieter Schaarschmidt & Paul L.M. van Giersbergen. (2003) Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin. Clinical Pharmacokinetics 42:3, pages 293-301.
Crossref
Crossref
Toshiro Konoike, Ken-ichi Matsumura, Tadahiko Yorifuji, Shoji Shinomoto, Yutaka Ide & Takashi Ohya. (2002) Practical Enantioselective Synthesis of Endothelin Antagonist S-1255 by Dynamic Resolution of 4-Methoxychromene-3-carboxylic Acid Intermediate. The Journal of Organic Chemistry 67:22, pages 7741-7749.
Crossref
Crossref
Jasper Dingemanse, Martine Clozel & Paul L. M. Van Giersbergen. (2002) Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. British Journal of Clinical Pharmacology 53:4, pages 355-362.
Crossref
Crossref